Seattle Genetics announced today that the FDA had accepted its BLA on its antibody drug conjugate (ADC), SGN-35 or brentuximab vedotin, for the treatment of Hodgkin's disease and anaplastic large cell lymphoma. This is good news for Seattle Genetics and the patients with these two diseases.
SeaGen FDA Deadline Set for Aug. 30.
SGN-35 will now receive a review date from the agency by August 30th. This new type of therapy for cancer is expected to pass muster at that time and would be the first ADC approved.
Posted by Bruce Lehr May 2nd 2011.
Comments